Clinical Trial Detail

NCT ID NCT02421939
Title A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine

Cytarabine + Fludarabine + Idarubicin

Cytarabine + Etoposide + Mitoxantrone

Azacitidine

Gilteritinib

Filgrastim

Age Groups: adult

Additional content available in CKB BOOST